This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Lonza Licenses ADC Tech to Antharis
Business licensing agreement

Lonza Licenses ADC Tech to Antharis

Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 18, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is positively impacted by this collaboration as it signifies advancement in oncology drug development, particularly for gastrointestinal cancers. Lonza Group's stock may see a positive reaction due to potential milestone and royalty payments, while Antharis Therapeutics gains a significant boost in its R&D capabilities, potentially attracting future investment.

biotechnology pharmaceuticals
Event Summary

Lonza Group and Antharis Therapeutics have announced an exclusive, target-specific licensing agreement to develop novel dual-payload Antibody-Drug Conjugates (ADCs) for gastrointestinal cancers. Under this agreement, Antharis Therapeutics will gain rights to Lonza Group's clinically validated dual-payload ADC technology platform, combining it with its own antibody engineering and target biology expertise. This collaboration aims to advance Antharis Therapeutics' lead ADC program, which is set to enter clinical trials. Lonza Group will be responsible for manufacturing components related to its proprietary payload and linker technologies and will receive upfront, milestone, and royalty payments from Antharis Therapeutics. Both companies express a shared commitment to developing innovative, biology-driven ADCs to overcome multi-drug resistance and improve patient survival rates in oncology.

Entities Involved
priv
Antharis Therapeutics
Antharis Therapeutics has secured an exclusive, target-specific licensing agreement with Lonza Group to develop novel dual-payload ADCs for gastrointestinal cancers. This agreement allows Antharis Therapeutics to integrate Lonza Group's clinically validated technology with its own expertise, advancing its lead ADC program into clinical trials and strengthening its position in oncology drug development.
Importance 95.0 Sentiment 70.0
stock
Lonza Group
Lonza Group has entered into an exclusive licensing agreement with Antharis Therapeutics, providing its dual-payload ADC technology platform. Lonza Group will manufacture components related to its proprietary payload and linker technologies and is eligible for upfront, milestone, and royalty payments, which is positive for its revenue streams.
Importance 90.0 Sentiment 60.0
per
Jan Vertommen
Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis at Lonza Group, commented on the licensing agreement, highlighting the innovation and potential of combining Lonza Group's platform with Antharis Therapeutics' expertise.
Importance 20.0 Sentiment 0.0
per
Raphael Ribeiro Pinaud
Raphael Ribeiro Pinaud, CEO of Antharis Therapeutics, emphasized the strategic importance of the collaboration, stating it positions Antharis Therapeutics to advance next-generation dual-payload ADCs.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.